A decision is expected in the fourth quarter of 2025.

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved. U.S.-listed shares of Novo added to session gains and were last up 5.72% at ...

Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...

Ozempic’s popularity for weight loss is growing, and according to a 2024 survey from KFF, about two in five adults in the US ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...

Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...

Ozempic may improve fertility if you have PCOS. In a 2023 study, 27 women with obesity and PCOS took a weekly 0.5-milligram ...

Though retrospective, the findings provide ‘compelling’ evidence that GLP-1 receptor agonists may help prevent development ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Keeping up with the GLP-1 area is a full-time job by itself. First off, you have the recent development that these drugs are ...